Status:
RECRUITING
Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Neuroendocrin Tumors.
Lead Sponsor:
IRCCS San Raffaele
Conditions:
Neuroendocrine Tumors
Eligibility:
All Genders
18+ years
Brief Summary
Neuroendocrine tumors (NETs) constitute approximately 0.5% of malignancies. To date, diagnosis at an increasingly early stage of the disease is possible thanks to recent technological advances in biom...
Eligibility Criteria
Inclusion
- Adult patients affected by neuroendocrine tumors; Patients who have performed at least one PET study with 18F-FDG and/or 68Ga- DOTATOC for the staging or diagnosis of their pathology.
Exclusion
- Patients \< 18 years old;
- Lack of availability of clinical data and PET imaging useful for analyses.
Key Trial Info
Start Date :
October 27 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 27 2024
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT06159920
Start Date
October 27 2021
End Date
December 27 2024
Last Update
March 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Irccs San Raffaele
Milan, Italia, Italy